Skip to main content

Table 1.

Overview of influenza polymerase inhibitors

Favipiravir Pimodivir Baloxavir marboxil
Alternative name T-705 JNJ-63623872, VX-787 S-033188
Molecular formula C5H4FN3O2 C20H19F2N5O2 C27H23F2N3O7S
Molecular weight 157.1 399.4 571.6
Active form Favipiravir-RTP Baloxavir acid
Target protein PB1 PB2 PA
Target influenza viruses Types A, B, C, D Type A Types A, B, C, D
Current status Approved in Japan for influenza pandemic preparedness In Phase III clinical trials Approved in several countries (Japan, USA, etc.)
Route of administration BID oral dose for 5 d BID oral dose for 5 d Single oral dose
Inhibition of M2 inhibitor–resistant viruses Yes Yes Yes
Inhibition of NA inhibitor–resistant viruses Yes Yes Yes
Emergence of variants with reduced susceptibility in vitro Yes Yes Yes
Emergence of variants with reduced susceptibility in clinical trials No Yes Yes

(Favipiravir-RTP) Favipiravir-ribofuranosyl-5′-triphosphate, (PB1) polymerase basic protein 1, (PB2) polymerase basic protein 2, (PA) polymerase acidic protein, (BID) twice daily, (M2) matrix protein 2, (NA) neuraminidase.